Skip to main content
. 2015 Dec 16;35(50):16463–16478. doi: 10.1523/JNEUROSCI.2131-15.2015

Figure 2.

Figure 2.

LBT-3627 is resistant to protease activities. A–C, Relative stabilities of three peptides, VIP (solid line and circles), LBT-3393 (dotted lines and open circle), and LBT-3627 (dotted lines and open triangles) after exposures up to 120 min to different aggressive protease environments of pepsin (A), proteinase K (B), and chymotrypsin (C). Percentage of nondegraded peptide concentrations remaining from time 0 were determined by RP-HPLC. D, Pharmacokinetic (PK) profile of 250 nmol/kg unformulated LBT-3627 drug concentration using LC-MS/MS analysis, with t½ = 24.33 min.